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Abstract 
 
The enzyme Erwinia chrysanthemi L-asparaginase (ErA) is an important 
biopharmaceutical product used in the treatment of Acute Lymphoblastic Leukaemia. 
Like all proteins, certain asparagine (Asn) residues of ErA are susceptible to deamidation 
to aspartic acid (Asp), which may be a concern with respect to enzyme activity and 
potentially to pharmaceutical efficacy. Recombinant ErA mutants containing Asn to Asp 
changes were expressed, purified and characterised. Two mutants with single deamidation 
sites (N41D and N281D) were found to have approximately the same specific activity 
(1062 and 924U/mg respectively) as the wild type (908U/mg). However, a double mutant 
(N41D N281D) had an increased specific activity (1261U/mg).   The N41D mutation 
conferred a slight increase in the catalytic constant (kcat 657 s
-1
) when compared to the WT 
(kcat 565 s
-1
), which was further increased in the double mutant, with a kcat of 798 s
-1
. 
Structural analyses showed that the slight changes caused by point mutation of Asn41 to 
Asp may have reduced the number of hydrogen bonds in this α-helical part of the protein 
structure, resulting in subtle changes in enzyme turnover, both structurally and 
catalytically. The increased α-helical content observed with the N41D mutation  by 
circular dichroism spectroscopy correlates with the difference in kcat, but not Km. The 
N281D mutation resulted in a lower glutaminase activity compared with WT and the 
N41D mutant, however the N281D mutation also imparted less stability to the enzyme at 
elevated temperatures. Taken as a whole, these data suggest that ErA deamidation at the 
Asn41 and Asn281 sites does not affect enzyme activity and should not be a concern during 
processing, storage, or clinical use. The production of recombinant deamidated variants 
has proven an effective and powerful means of studying the effect of these changes and 
may be a useful strategy for other biopharmaceutical products. 
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1. Introduction 
 
One of the mainstays used in clinical treatment of acute lymphoblastic leukaemia (ALL) is 
L-asparaginase (E.C. 3.5.1.1) [1]. Leukaemic cells require asparagine (Asn) to survive 
and proliferate, and L-asparaginase removes this essential nutrient by converting it to 
aspartic acid (Asp) [2]. Currently, there are two enzymes available for clinical use in the 
treatment of ALL: Escherichia coli L-asparaginase (EcA) and Erwinia chrysanthemi L- 
asparaginase (ErA). Historically, EcA has been the first treatment given clinically, but 
approximately 30% of patients develop a hypersensitivity to EcA, in which case ErA is 
utilised [3,4]. 
Like many enzymes in the asparaginase family, ErA is a 140,000Da homotetramer in its 
active form. ErA is a basic protein with an isoelectric point of pH 8.6 [5] and each subunit 
of the tetramer consists of 327 amino acids. The crystal structure of ErA has been solved 
to <1.8Å resolution [6, 7, 8] with a number of different substrates, and the enzyme overall 
structure has 222 symmetry and an active site mediated by residues Thr15, Glu63, Asp96, 
Ser62, Thr95 and Ala120 [6]. 
In common with many older biotechnology products, the manufacture of ErA is complex 
and lengthy. ErA continues to be the focus of an intensive effort to fully understand the 
complex process and further characterise the product [9]. In the manufacture of 
therapeutic enzymes, it is an important regulatory requirement to understand and 
characterise the main degradation and inactivation pathways that occur during protein 
expression,  purification  and  storage.     Such  pathways  generally  involve  oxidative 
processes, protein-protein aggregation, and amino acid side chain modifications including 
deamidation. 
Deamidation is probably the most difficult of these pathways to characterise, frequently 
occuring in proteins both in vivo and in vitro [10]. Deamidation is most common in Asn 
residues but is also possible in glutamine (Gln). The deamidation mechanism of an Asn 
side chain starts with the C-terminal α-nitrogen attacking the Asn side-chain carboxylate 
group, resulting in a cyclic succinimide intermediate and evolution of ammonia. The 
succinimide group is then hydrolysed to form a mixture of Asp and isoAsp [11]. A 
deamidation event leads to a lowering of the protein pI due to the change in residue charge 
from neutral to negative, leading to charge heterogeneity in protein products. 
The overall effect of deamidation of a particular protein Asn residue may be deleterious to 
enzyme activity, structure or protein function [10,11]. In biopharmaceutical protein 
products such as monoclonal antibodies and ErA, deamidation may occur during 
manufacture or storage, and therefore must be characterised and monitored to understand 
if there is any impact on protein function. Limiting the amount of process-induced 
deamidation was studied recently for ErA [12], but the exact nature of the deamidated 
species, especially deamidation at particular sites, was not fully determined. The impact 
of a particular deamidation event is difficult to characterise fully. Understanding the 
impact of deamidation (and charge-variants in general) usually involves isolation using 
preparative HPLC and may be extremely laborious [13,14]. The isolated species may 
have multiple post-translational modifications, making it difficult to address the impact of 
a particular modification on protein or enzyme function. Finally, the HPLC-isolated 
charge variants may have a different stability profile, further complicating matters. 
L-asparaginase is a good model for studying the effect of deamidation, as the activity of 
the enzyme depends on maintaining the quaternary structure. Thus, in addition to 
deamidation near the active site residues, deamidation that changes the affinity of the 
monomeric proteins may also affect enzyme activity. French and German researchers first 
studied EcA deamidation using isoelectric focusing in the 1970s [15,16,17]. More 
recently, researchers have used two-dimensional gel electrophoresis to separate post- 
translationally modified forms (including deamidated forms) of EcA and ErA [18]. 
In the present study, recombinant deamidated forms of ErA were produced, and 
characterised to understand the impact of asparaginyl deamidation on the physicochemical 
parameters and enzyme activity. A similar strategy has been employed [19, 20] to 
investigate the impact of particular deamidation sites on the structure and function of 
human lens αB-crystallin. The advantages and disadvantages of using this strategy to 
investigate charge variants of biopharmaceutically important proteins such as ErA is 
discussed. 
 
 
 
 
 
 
2. Materials and Methods 
 
Recombinant Protein Expression: 
 
Reagents used were obtained from Sigma (Gillingham, UK) unless otherwise indicated. 
The Erwinia chrysanthemi NCPPB 1066 wild type gene [21] and deamidated mutants 
were synthesised by DNA2.0 (California, USA). Each mutant gene was sequence verified 
and inserted using NdeI and BamHI restriction sites into a pJ401 expression vector 
incorporating a T5 promoter [22, 23, 24, 25], kanamycin resistance gene, and lacI/lacO 
repression system. The plasmids were stored at -20°C until needed, and transformed into 
the BL21 strain of Escherichia coli from New England Biolabs (Hitchin, UK) using a 
standard heat-shock protocol. Transformation cultures were grown overnight at 37ºC on 
Luria-Bertani (LB) agar selection plates containing 50µg/mL kanamycin sulphate. Single 
colonies were selected from the transformation plates and grown in 2L shake flasks 
(600mL working volume) at 37ºC in terrific broth (TB) with added 100µg/mL kanamycin 
sulphate and 5mM MgCl2. Cultures were monitored for optical density at 600nm and 
upon reaching an OD600 in the range 0.6 – 1.0, were induced by addition of isopropyl β-D- 
1-thiogalactopyranoside (IPTG) to a final concentration of 1mM. Cultures were further 
grown post-IPTG addition overnight at 22 - 28ºC and harvested in a Beckman J-25 
centrifuge and JLA-16250 (High Wycombe, UK) rotor at 4000rpm and 4ºC for 30min. 
Cell pellets were stored at -20ºC until needed for further processing. 
 
 
 
Recombinant Protein Purification: 
 
Isolation of the wild-type and mutant ErA enzymes was performed using a procedure 
modified from the methods of Kotzia et al. [26] and Lee et al. [27]. Briefly, cell pellets 
were reconstituted in 10mM sodium phosphate pH 7.5 containing 100mM NaCl and 
treated with protease inhibitor cocktail (SigmaFast, Sigma, Gillingham, UK). The cells 
were disrupted on ice using a SoniPrep150 (MSE, London, UK) in three 45s bursts. The 
disrupted lysate was cleared of debris using a Beckman J-25 centrifuge (High Wycombe, 
UK) and JA25-50 rotor at 11,000rpm for 45min at 4ºC. The cleared lysate was then 
applied to a L-Asn affinity column prepared and equilibrated as described previously, and 
eluted using a gradient of 10mM L-Asn in the equilibration buffer. Fractions  were 
collected and pooled based on SDS-PAGE and extensively dialysed against 18.2MΩ water 
in a 10kDa molecular-weight cut-off (MWCO) Snakeskin™ dialysis membrane 
(ThermoFisher, Loughborough, UK). The dialysate was concentrated using Amicon™ 
Ultra-15 regenerated cellulose 10kDa MWCO spin concentrators (Millipore, Watford, 
UK) and aliquotted for frozen storage at -20ºC. 
 
 
 
Protein and Activity Assays: 
 
The protein content of all samples described in this work was determined using a UV 
absorbance measurement with the known extinction coefficient for ErA, or using the 
method of Lowry [28]. The asparaginase activity assay was performed in borate buffer by 
measuring the decrease of the amide bond absorption of asparagine at 225nm as described 
previously [29]. The pH dependence of activity determined by using the 225nm assay in 
various buffers (phosphate or borate depending on the desired pH) and true system pH 
values were measured in the presence of substrate and enzyme. Analyses of the 225nm 
absorption of the buffer, substrate, and enzyme, each in isolation were conducted, to 
correct for any non-specific effects. 
 
 
 
Km and kcat Determination: 
 
Since absorbance changes for substrate concentrations in the region of Km are too small to 
measure with the 225nm assay, the kinetic constants were determined by conducting 
enzyme reactions at various L-Asn substrate concentrations, with post-reaction 
derivatisation of the reaction product L-aspartic acid with 6-aminoquinolyl-N- 
hydroxysuccinimidyl  carbamate  (AQC).    The  derivatisation  has  the  dual  function  of 
stopping the enzyme reaction as well as allowing quantification of the labelled product by 
the use of UPLC with uv detection. 
L-asparagine was added to 194 mM sodium borate pH 8.6 + 0.005% w/v bovine serum 
albumin (BSA) at 7.5, 12.9, 20, 30, 45, 70, 120 and 270 µM (chosen to give rate data at 
10% intervals relative to Vmax, based on a model with Km set at 30 µM). Asparaginase 
samples were diluted in the same buffer containing 0.03% w/v BRIJ 35 to a calculated 
activity of 0.06 U/mL. A 9.9 mL aliquot of each substrate solution was equilibrated in a 
water bath to 37°C and 0.1 mL of sample was added. After a timed interval calculated to 
give approximately 10% substrate conversion at each concentration, 0.1 mL of the 
reaction mixture was withdrawn and mixed with 0.015 mL of AQC derivatisation reagent 
(AccQ-Tag Ultra; Waters Corp.) in a total recovery vial. This has been demonstrated to be 
sufficient to stop the reaction rapidly. Derivatised L-aspartic acid was then measured using 
a Waters Acquity UPLC system according to the manufacturers recommended protocol. 
L-aspartic acid dilutions were run as calibrants and results for the enzyme reactions were 
corrected for the initial presence of contaminating L-aspartic acid in the L-asparagine 
stock. Km and Vmax values were calculated by non-linear regression using GraphPad Prism 
5 software. Values for kcat were calculated from the Vmax values by using the protein 
concentration determined by UV absorbance and a molecular weight per active site of 
35,054 Daltons. 
 
 
 
Glutaminase Assay: 
 
An HPLC-based method for measuring glutaminase activity at pH 8.6 was used, similar to 
that described above for the Km and kcat. L-glutamine was used as the substrate at three 
concentrations (89, 243 and 463 µM).  Low substrate concentrations were tested, because 
previous experiments have shown apparent substrate inhibition for the glutaminase 
reaction of Erwinia chrysanthemi L-asparaginase. The enzymes were each added at the 
same measured asparaginase activity (final activity 0.061 U/ml) and reactions were run for 
a fixed time of 30 minutes at 37°C before derivatisation and HPLC measurement against 
known glutamate standards as described above. The maximum substrate conversion was 
27%. 
 
 
 
WCX Assay: 
 
Samples were assayed for charge profile using a previously described weak cation 
exchange (WCX) HPLC method [12]. Briefly, a Dionex ProPac WCX-10 column 
(Dionex, Leeds, UK) was used with a gradient from 10 to 300mM sodium chloride in pH 
6.2 sodium phosphate buffer, and absorbance data collected at a wavelength of 220nm. 
 
 
 
 
Isoelectric Focusing: 
 
Isoelectric focussing (IEF) of ErA samples was conducted using two separate techniques. 
In the first instance, Novex™ gels and running buffers from Invitrogen (Paisley, UK) were 
used to analyse the samples between the pH range 3-10. The IEF 3-10 gels were focused 
using a three step voltage protocol (100V for 1h, 200V for 1h, and 500V for 30min) and 
fixed in 12% trichloroacetic acid (TCA) before staining with Invitrogen SafeStain™. 
Samples were also analysed using Lonza IsoGel Agarose IEF plates in the pH range 7-11. 
Samples were electrophoretically focused using a Multiphor II (GE Healthcare, 
Amersham, UK) system at 1000V constant voltage with a power limit of 25W, using 
0.01M  glacial  acetic  acid  as  the  anolyte  and  Cathode  Fluid  10  (Serva,  Heidelberg, 
Germany) as the catholyte. Immediately upon removal of the voltage, the IEF plate was 
fixed in aqueous TCA containing methanol and sulphosalicylic acid. After fixing, the gel 
plate was thoroughly washed and dried and stained with Coomassie Brilliant Blue R-250 
(Bio-Rad, Hemel Hempstead, UK) in a mixture of water, acetic acid and ethanol. Gels 
were imaged using a Bio-Rad GS-800 densitometer. 
 
 
 
SDS-PAGE: 
 
Analysis by SDS-PAGE was conducted using Novex™ 4-12% Bis-Tris gels from 
Invitrogen (Paisley, UK) with MES running buffer and Invitrogen Mark12™ ladder. The 
electrophoresis was conducted for 35min at 200V constant voltage and gels were stained 
in SafeStain from Invitrogen.  Gels were imaged using a Bio-Rad GS-800 densitometer. 
 
 
 
Enzyme Stability Experiments: 
 
The effects of both thermal and denaturing stress on the enzymatic activity were assessed 
using methods adapted from Papageorgiou et al [30]. Briefly, for thermal stress, enzyme 
aliquots were diluted to 20 U/mL in 50mM sodium phosphate buffer pH7.2, mixed and 
incubated at a given temperature for 3min using a water bath. The enzyme aliquots were 
then stored on ice for at least 1h before measurement of activity using the UV assay 
described above. For denaturing stress experiments, 250U/mL enzyme stocks  were 
diluted (16µl enzyme plus 144µl denaturant) with various concentrations of urea in 50mM 
sodium phosphate pH7.2. The enzymes were held at room temperature (23°C) for 1h in 
denaturant, then assayed for activity using the UV method described above. The UV 
assay uses a 1 in 100 dilution factor which was utilised as a rapid refolding step. 
Circular Dichroism Analyses: 
 
Circular dichroism (CD) analyses were performed using a Jasco J-715 spectropolarimeter 
at Alta Bioscience (Birmingham, UK). The analyses were carried out between 280 and 
190nm, using samples were provided in analytical-grade water (AGW); a sample of AGW 
was used as a blank. The deconvolution of the spectra was performed using Dichroweb 
[31 - 33]. 
 
 
 
Molecular sequence and structure analyses: 
 
Sequence alignments were performed using Clustal Omega [34] and depicted using 
Espript [35]. Molecular graphics and analyses were performed with the UCSF Chimera 
package [36]. Chimera is developed by the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIGMS P41- 
GM103311) 
 
 
 
3.0 Results and Discussion 
 
The manufacturing process for ErA has been discussed previously [9, 37] and has recently 
been the focus of on-going efforts to fully characterise the product and define the 
operating parameters for its production. During processing, oxidised, aggregated and 
deamidated species may be created. A key part of controlling the process is ensuring that 
these species are kept within certain limits, to ensure product consistency. Measurement 
of deamidated protein species may be made using the WCX HPLC assay, IEF, or mass 
spectrometry methods. However, quantitation of these species and understanding their 
impact  on  the  final  biopharmaceutical  preparation  are  two  separate  matters.    A  full 
understanding of the functional activity of deamidated proteins requires their isolation as 
relatively pure species. Deamidated species can be isolated using preparative HPLC 
techniques, but the isolated peaks often contain tiny amounts of protein, meaning many 
repeat injections to produce enough material for further study. Furthermore, the isolated 
species often contain multiple post-translational modifications, making understanding the 
impact of single modifications (i.e., deamidation at a particular site) difficult or 
impossible. 
Therefore, the production of recombinant deamidated ErA species was determined as an 
appropriate strategy to attempt to understand their contribution or impact on efficacy in the 
clinical use of the enzyme. Likely ErA deamidation sites were identified using existing 
mass spectral data (data not shown), and the ErA sequence [21] was then analysed to 
determine which Asn residues were most likely to deamidate based on previous work in 
the literature [38, 39, 40]. The rate of deamidation depends on the amino acid residue on 
the C-terminal side of Asn, with Gly being the most reactive followed by Ala. Previous 
work had shown that Asn281 [12] is a likely candidate for deamidation with the sequence 
N281G282, even though, based on published crystal structures [6, 7, 8], its location lies 
buried inside the tetrameric assembly. When the available crystal  structures  were 
analysed using molecular modelling software a further candidate, Asn41 was identified, 
with the sequence N41A42. Asn41 is a particularly interesting site as it occupies a solvent- 
exposed position on the protein, regardless of whether the enzyme is assembled as a 
tetramer or in its monomeric state. This makes Asn41 potentially prone to deamidation at 
any time during its production, storage or use. The positions of both of these (Asn41 and 
Asn281) potential deamidation sites (Figure 1A) are located away from the active site and 
were selected for further study as recombinant deamidated mutants. In comparison with 
other bacterial L-asparaginases (Figure 1B), ErA Asn41 is conserved in EcA and has high 
similarity with Gln41 in the Erwinia carotovora L-asparaginase (EwA), while Asn281 is a 
Ser residue in both EcA and EwA. One important point to note regarding the recombinant 
deamidation strategy is the inability to produce deamidated protein containing iso-Asp 
residues, which are a product of the natural reaction but cannot be made by recombinant 
means. 
Four versions of ErA were produced in this study: wild-type (WT) ErA, N41D, N281D 
and a double mutant, N41D N281D. Production of the recombinant proteins (Figure 2) 
was monitored using SDS-PAGE. The gel depicted is for the WT enzyme and is 
representative of the production of all four recombinant proteins, which were grown 
simultaneously in shake flasks. Final enzyme yields for the WT, N41D and N281D 
proteins were approximately 3.9 – 5.1mg/L culture, but the double mutant exhibited a 
markedly increased production of 10.3mg/L culture. Lysates from all of these 
preparations were analysed by SDS-PAGE and it appeared that the double mutant N41D 
N281D exhibited higher levels of production. It is not understood why this mutant may 
have expressed at higher levels. The final preparations of all four recombinant enzymes 
(Figure 3) appeared homogeneous as judged by SDS-PAGE. 
The recombinant protein preparations were studied for charge differences using IEF. The 
IEF gels (Figure 4) were run in two ways, first on vertical gels with a wide pH range (3 – 
10) and then on ultrathin agarose gels with a narrow pH range (7 - 11). The wide-range 
gel image demonstrates the relative homogeneity of each protein sample and the lack of 
contaminating bands in the low-pI region (<7), demonstrating that the samples contained 
the alkaline ErA variants and not the acidic EcA enzyme, which would have been present 
in small amounts in the host cell. Due to the wide pH range of this gel and the high pI of 
ErA, some of the protein bands appear very near or even at the level of the sample wells. 
Therefore, higher-resolution flat bed electrophoresis was performed in the more narrow 
pH range between 7 and 11. This gel, also pictured in Figure 4, shows that the WT and 
N281D enzymes have roughly the same pI, as do the N41D and the double mutant. 
Interestingly, the contribution of the internal mutation N281D to the enzyme’s pI is 
negligible, in the case of both the single mutant N281D and the double mutant N41D 
N281D. 
Using the more sensitive WCX HPLC assay (Figure 5), subtle differences in charge 
variation can be observed. However, the general trend is that there are two groups of 
charged species, N281D and the WT enzymes forming one group, and N41D and the 
double mutant forming the second, with retention times only just after the HPLC void 
peak. The N41D and double mutant species have the largest charge differences to the WT 
enzyme, at -1 per monomer or -4 per tetramer. As discussed previously [12], the acidic 
(putative deamidated) species observed during routine manufacture of ErA elute at relative 
retention times (RRT) between 0.7 and 1.0 in this assay. These data taken together 
suggest that the species routinely observed in ErA clinical preparations are only 
marginally deamidated, and either have internal modifications (like N281D) or have fewer 
modifications per tetramer, e.g., only one monomeric subunit is deamidated per tetramer. 
An important point to address regarding the deamidated mutants is whether they retain 
enzymatic activity.  The activity of each mutant was tested in triplicate in borate buffer pH 
8.6 at 37°C using L-asparagine as the substrate, and the data (Table 1) demonstrate that 
unexpectedly, the double mutant has a higher specific activity than the WT or single- 
mutant enzymes, which are all relatively similar. The glutaminase activity of the 
recombinant enzymes was also determined and found to be low compared to asparaginase 
activity. However, the internal mutation N281D appeared to correlate with a lower 
glutaminase activity in both the single (N281D) and double (N281D N41D) mutants 
compared with the WT and the N41D enzymes. 
In order to further understand the differences observed in activity, the enzymatic catalytic 
constants Km and kcat for L-Asn were determined for each of the four  recombinant 
enzymes (Table 2). Michaelis-Menten plots from these analyses (Figure 6) demonstrate 
the robustness of the kinetic data. The results confirmed the observations made from the 
native-substrate activity data, and demonstrate that an apparent synergistic effect of the 
two mutations (N41D and N281D) raises the catalytic performance of ErA beyond the WT 
or the corresponding single-mutant species. Mutation N281D appears to result in a 
decreased substrate affinity by a factor of 2, and this effect is also observed for the double 
mutant compared to the WT. Mutation N41D does not change the Km value, but results in 
a marginally higher turnover number (657 vs 565 s
-1
). However, the species with both 
mutations has even higher catalytic efficiency (798 s
-1
). The possible reasons for this 
observed effect are discussed below. 
 
The stability profiles of the ErA mutants were assessed in terms of enzymatic activity 
using comparative experiments adapted from Papageorgiou et al [30]. The results (Figure 
7A) for the thermal stability study illustrated that both enzymes carrying the N281D 
mutation, internal to the quaternary structure, resulted in thermal inactivation at a lower 
temperature (approximately 43ºC and greater) than those without the mutation (≥56 ºC). 
Incubation of N281D and the double mutant at 49ºC for 3min resulted in loss of 
approximately 50% of enzymatic activity, while this temperature had no effect on the 
activity of the WT or N41D enzymes. The external mutation N41D appeared to have no 
effect on the enzyme stability, correlating well with the thermal stability profile of the wild 
type ErA. The residual enzyme activity after exposure to denaturing conditions was also 
examined, and similar to the thermal profiles, the N281D mutation resulted in an inability 
to refold after exposure to urea concentrations greater than 1.5M (Figure 7B), while the 
external N41D mutation had no impact on the stability of the enzyme.   Linear enzyme 
reaction curves were obtained in all cases (data not shown), suggesting that rapid enzyme 
refolding had occurred and not interfered with the activity results. These stability results 
correlate well with the Km data in Table 2, suggesting that any structural differences 
caused by the N281D mutation, internal to the tetrameric structure, cause a decrease in 
substrate affinity as well as a decrease in the stability profile. After denaturation with 
urea, the ability of the enzyme to refold into the active, quaternary structure is affected, 
suggesting that N281 may play an important role in the folding pathway for this enzyme. 
Similar observations have been made for other multimeric, subunit enzymes with point 
mutations after denaturation in urea [41]. 
In order to ensure that the higher activity and enzymatic constants observed for the double 
mutant N41D N281D were not an artefact of a shifted optimum in the  relationship 
between pH and activity, the relationship was investigated using the UV activity assay 
with substrate in buffers of various pH values between 6.5 and 10. The data (Figure 8) 
demonstrate that there is no gross difference in the pH versus activity relationship for the 
double mutant when compared with the WT. The data are presented as points, with a 
dynamic 4-parameter Gaussian fit also shown, calculated using SigmaPlot (Systat, 
California, USA). 
As the increased catalytic performance of the double mutant N41D N281D over the WT 
could not be easily explained by differences in the pH-activity curves, potential structural 
differences were investigated. The four recombinant enzymes were analysed using 
circular dichroism (CD) spectroscopy (Figure 9, Table 3), which showed a substantial 
difference between enzymes containing the N41D mutation (N41D and the double mutant) 
and those without this mutation. The data suggest that the N41D mutation has structurally 
altered the existing α-helix in this region to make it more detectable, as demonstrated by 
the increased signal compared to both WT and N281D at 222nm.  Using the deconvoluted 
CD data, there appears to be a correlation between kcat and the increase in α-helical content 
conferred by the N41D mutation, but no apparent correlation of the CD structural analysis 
(α-helix or β-sheet) with differences observed in the Km of the various mutants. This 
suggests that the N41D mutation affects turnover but not substrate affinity, and given the 
location of this mutation near to the active-site loop, these results may make physical 
sense. Changes to CD spectra have been shown to correlate with differences in EcA 
catalytic constants previously, with fatty-acid L-asparaginase conjugates  showing 
lowering of both Km and β-sheet content compared to the native enzyme [42]. Further, 
increases in β-sheet and decreases in α-helical content have been shown to correlate with 
decreased activity for ErA [43]. 
Therefore, to further understand the structural differences observed by CD in these ErA 
mutants, published crystal structures from the Protein Data Bank (PDB) were used (entries 
1O7J, 1HG1 and 1HFW) [6, 7, 8] with the CHIMERA molecular visualisation software. 
Hydrogen bonding opportunities were calculated using the CHIMERA software which is 
based on published methods [44]. Rotamers chosen for analysis were the most probable 
conformations based on probability, hydrogen bonding and avoidance of clashes using the 
methods of Dunbrack [45]. Interestingly, both mutations appear to result in a slightly 
lower number of hydrogen bonds in the surrounding structural microenvironment. The 
N41D mutation (Figure 10A) results in loss of a hydrogen bond between the Asn41 
sidechain amide and the peptide bond carbonyl group of Asp37. This change may slightly 
slacken the position of the α-helix, potentially causing greater mobility of the flexible 
active site lid-loop which is N-terminal to this helix. This structural possibility would be 
consistent with the observed increase in the catalytic turnover of the N41D mutant as 
evidenced by the increase in kcat. 
The N281D mutation (Figure 10B) may also cause loss of a hydrogen bonding opportunity 
with one of the other chains (in the Figure, Chains A and C are shown) in the tetrameric 
enzyme structure. In the WT enzyme, the sidechain amide of Asn281 forms a hydrogen 
bond with the peptide carbonyl group of Ala171 on the opposite protein monomer. 
Considering that, in the case of the tetrameric assembly, this effect will occur four times in 
the mutant compared with the WT, it is possible that the N281D mutant tetramer is held 
together with slightly less strength, resulting in a slightly slacker structure. As each active 
site in the ErA tetramer involves residues from two separate chains, it is possible that the 
slightly looser tetrameric structure resulting from the N281D mutation results in a slightly 
wider entrance to the active site, which would be consistent with the observed increase in 
the Km (as well as the consequent decrease in substrate affinity, thermal stability and 
denaturing stability) for the N281D mutation. 
The published EwA crystal structure [30] was consulted to further understand the 
structural effects of the two mutations in ErA. EwA is an enzyme with 79% identity to 
ErA, from a very similar organism, and is a good basis of comparison from a structural 
point of view. Using PDB entry 2JK0 and the Chimera molecular viewing software, the 
structural hydrogen bonding environments around these two amino acid positions were 
studied. In comparison with wild type ErA, which has two hydrogen bonds originating at 
position 41 as described above, in EwA there is only one hydrogen bond between the 
peptide bond nitrogen at position 41 (Gln41) and the peptide bond oxygen at position 37 
(Glu37). EwA lacks the additional hydrogen bond observed in WT ErA between the side 
chain of residue 41 and the peptide-bond oxygen of position 37, making EwA structurally 
more like the ErA N41D mutant. This may help explain why the ErA N41D mutation 
results in a higher kcat compared with ErA WT, as the EwA kcat  is also higher than ErA 
WT at 1600s
-1  
[46].   Furthermore, at position 281, the Ser residue in EwA has two 
hydrogen bonds between protein chains, one originating from the peptide bond oxygen at 
position 281 and one originating from the Ser281 sidechain. The ErA wild type enzyme 
has three hydrogen bonds from position 281, reducing to two in the N281D mutant, 
making EwA more like the ErA N281D mutation in terms of the number of hydrogen 
bonds in this region. The reported value of EwA Km is 98µM [46], and the observation 
that at position 281 EwA is structurally akin to ErA N281D correlates with the observed 
difference in Km between the N281D and WT ErA enzymes. Furthermore, the number of 
hydrogen bonds at this site (3 in ErA WT, 2 in ErA N281D and EwA) appears to correlate 
with the lower glutaminase activity [47] and decreased stability both observed for EwA 
[30], which like N281D was less stable at urea concentrations greater than 1.5M and 
temperatures greater than 45ºC. 
The empirical findings in this study appear to be further supported by analysis of the 
mutations using computational prediction methods. The N41D mutation was predicted to 
have no effect on the α-helical local structure at this site using the I-TASSER prediction 
tools [48, 49, 50]. A check of the effect of the N281D mutation on the binding efficiency 
of the monomer subunits into tetramer was also performed using the Beatmusic server 
[51], with the calculation run as the interaction between two dimeric subunits (AB and 
CD) to return the full binding effect on the overall tetrameric assembly. As may be 
expected, the results showed that the N281D mutation is predicted to cause a significant 
decrease in binding affinity (ΔΔGbind), of 3.87kcal/mol, which appears to support the 
hydrogen-bonding structural analysis discussed above. Finally, both mutations were run 
through the AUTO-MUTE prediction server [52 - 54] which calculated that neither 
mutation should have a deleterious effect on enzyme activity, a result that supports the 
overall activity data in Table 1. 
4. Conclusions 
 
In order to understand the effect of deamidation on ErA, several recombinant mutants 
were expressed, purified and characterised. The locations of the  two  mutation  sites 
studied were both quite distal to the catalytic site of the enzyme. Surprisingly, the 
deamidated mutants of ErA had the same, or better, activity as the wild-type enzyme. In 
particular, a double mutant (N41D N281D) had increased activity and turnover compared 
with the wild-type. The N41D mutation alone conferred a subtle increase in turnover and 
the N281D mutation (alone or in concert with N41D) decreased both the stability and the 
substrate affinity of the enzyme. These effects may be due to subtle structural changes in 
the hydrogen bonding network around these mutation sites, particularly for the α-helix 
structure around N41D, differences in which could be detected by CD. Both mutations 
appear to affect the structural hydrogen bonding network of the enzyme, producing 
structures mimicking the closely-related EwA, which like N41D also has a higher catalytic 
constant and like N281D has a lower glutaminase activity and thermal stability, compared 
with ErA. 
Study of the effects of point mutations on enzymatic structure and activity remains an 
activity with a significant empirical component. Recent studies on L-asparaginase from 
Erwinia carotovora [55], which has 74% identity to ErA, showed that a single mutation 
(Gly to Ser) in a different, α-helical region somewhat distant to the active site, 
significantly decreased the catalytic performance of the enzyme. Studies to address the 
effects of Asn to Asp deamidation by mutation analysis must therefore be carried out on a 
case-by-case basis. 
The work presented in this paper suggests that ErA deamidation at the N41 and N281 sites 
should not be a concern during processing, storage or clinical use.   These deamidated 
variants of ErA are active and stable under normal storage conditions. Of course, 
deamidation content of these and other sites should still be monitored, but this work has 
provided scientific rationale of the true impact of deamidation on ErA activity at these 
particular sites. This strategy may be useful, and should be considered, as part of a holistic 
approach when investigating the impact of deamidation on other ErA sites, or other 
biopharmaceutical products. 
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Figure 1. Structural Details of ErA Mutants. (A) Location of N41D  and  N281D 
mutations in ErA tetramer. The image was created using PDB structure file 1O7J and 
CHIMERA molecular viewing software. One of the four subunits is shown in blue and 
the other three are shown in grey. The location of the flexible lid-loop for the blue subunit 
is shown in red. The location of N41 is shown in pink, and the location of N281 is shown 
in orange. (B) Sequence alignments of ErA, EcA and EwA made using Clustal Omega and 
depicted using Espript. The sequence alignment is annotated with secondary structure 
features from PDB file 1O7J. 
  
 
 
 
 
 
 
Figure 2. Purification of Recombinant ErA WT Enzyme. M – Mark12™ molecular 
weight marker; Lys – Cleared Lysate; FT – Chromatography Flow Through; Pool – 
Chromatography Enzyme Pool. 
  
 
Figure  3. SDS-PAGE  Analysis  of  Final  Recombinant  ErA  Enzymes. The  enzyme 
loading per well was 0.5µg/mL as judged by A280 protein concentration. 
  
 
 
 
Figure 4.  Isoelectric Focussing Analyses of Recombinant Deamidated ErA Mutants.  M – 
Serva 3 – 10 pI Marker. 
  
 
Figure 5. Weak Cation-Exchange HPLC Analyses of Recombinant ErA Mutants. The 
data are presented as traces using Relative Absorbance (normalised to the main-peak 
maximum) and Relative Retention Time (normalised to the main-peak retention of the WT 
enzyme). 
  
 
Figure 6. Michaelis-Menten plots. Eight data points at different substrate concentrations 
were generated for each recombinant enzyme. One outlier has been excluded for N41D. 
The R
2 
values, indicating goodness of fit, were: WT 0.9995, N41D 0.9995,  N291D 
0.9993, and N41D N281D 0.9998. 
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Figure 7.  Stability Profiles of ErA WT and Mutant Enzymes. The data are presented as 
residual remaining activity after exposure to thermal stress (A) or denaturation in urea (B). 
 
 
 
 
Figure 8.  Effect of pH on Activity of Recombinant ErA Mutants. 
  
 
Figure 9.  Circular Dichroism Spectra.  The data are presented as spectra with the solvent 
background (analytical-grade water) subtracted. 
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Figure 10. Hydrogen Bonding of ErA Mutations. (A) N41 Site in both Mutant and WT 
Enzymes. Only the hydrogen bonds originating from position 41 are depicted (by dashed 
lines) for both the WT (N41) and mutant (D41). The position of the substrate (here D- 
aspartate) is shown for reference. (B) Only the hydrogen bonds originating from position 
281 are depicted (by dashed lines) for both the WT (N281) and the mutant (D281). The 
A-chain of the tetramer is shown in blue, and the C-chain of the tetramer is shown in pink. 
  
 
Table 1. L-Asparagine Activity and Specific Activity and Glutaminase Activity of 
Recombinant ErA Deamidated Mutants. For L-Asn as a substrate, each activity data point 
represents the mean of six separate observations (measured on two different days each in 
triplicate). The relative standard deviation (RSD) for all L-Asn activity observations is 
also shown, for each enzyme. For L-Gln as a substrate, glutaminase data are reported as a 
ratio to asparaginase activity. 
 
Enzyme L-Asn 
Specific 
Activity 
(U/mg) 
L-Asn 
Activity 
(U/mL) 
L-Asn 
Activity RSD 
(%) 
L-Gln 
Activity 
(Ratio to L- 
Asn Activity, 
%) 
WT 908 698 (n=6) 1.5% 4.5% 
N41D 1062 1072 (n=6) 2.0% 4.1% 
N281D 924 776 (n=6) 3.3% 1.9% 
N41D 
N281D 
1261 1551 (n=6) 2.0% 1.8% 
Table 2. Km and kcat Data for Recombinant ErA Deamidated Mutants. Data shown are 
for the substrate L-Asn. Confidence limits refer to a non-linear regression fit to a single 
data set. Purified native ErA was also tested twice for reference, giving Km values of 28.9 
and 31.5 µM with kcat values of 647 and 646 s
-1 
respectively. 
 
 
Enzyme Km (µM) Km 95% 
confidence 
limits (µM) 
kcat (s
-1
) kcat 95% 
confidence 
limits (s
-1
) 
WT 29.1 27.8 - 30.4 565 556 - 574 
N41D 29.1 27.6 - 30.7 657 646 - 669 
N281D 59.7 55.6 - 63.8 573 557 - 590 
N41D N281D 56.2 54.2 - 58.3 798 786 - 810 
Table 3.  CD Deconvolution Results using DICHROWEB. 
 
 
Enzyme α-Helix Content 
(%) 
β-Sheet Content 
(%) 
Turns 
(%) 
Unstructured 
(%) 
WT 21 23 19 38 
N41D 37 12 20 32 
N281D 15 26 18 41 
N41D N281D 36 13 20 32 
 
